Factor V

2022 U.S. Coagulation Testing Market Report: Identify and Evaluate Emerging Business Opportunities - ResearchAndMarkets.com

Retrieved on: 
Tuesday, November 1, 2022
Research, Managed Care, General Health, Medical Devices, Hospitals, Health Technology, Clinical Trials, Science, Surgery, Biotechnology, Other Science, Health, ACT, Factor VII, Factor XII, Factor, Factor XI, Factor IX, APTT, Protein S, Activated protein C resistance, Thrombin time, Antithrombin, Bleeding time, Protein C, Factor X, Prothrombin time, Consumables, Factor V, Factor VIII, Prekallikrein, Comparison, Factor XIII, Fibrinogen, Marketing, Retail, Vaccine, Fine chemical, Pharmaceutical industry, Plasmin

The "2022 U.S. Coagulation Testing Market - Analyzers and Consumables - Supplier Shares, Segment Volume and Sales Forecasts for over 40 Assays, Opportunities" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "2022 U.S. Coagulation Testing Market - Analyzers and Consumables - Supplier Shares, Segment Volume and Sales Forecasts for over 40 Assays, Opportunities" report has been added to ResearchAndMarkets.com's offering.
  • This comprehensive report is designed to help current suppliers and potential market entrants identify and evaluate emerging business opportunities in the US coagulation testing market during the next five years.
  • The report is available by section, and can be customized to specific information needs and budget.
  • The report explores business and technological trends in the US coagulation testing market; provides estimates of the test volume, as well as sales and market shares of leading competitors; compares features of major analyzers; profiles leading market players; and identifies specific product and business opportunities facing instrument and consumable suppliers during the next five years.

Global Coagulation Testing Lab and POC Market (2022 to 2026) - Analysis of Current and Emerging Technologies and Their Potential Market Applications - ResearchAndMarkets.com

Retrieved on: 
Tuesday, April 26, 2022
Health, Medical Devices, Cardiology, ACT, Computer, Factor VII, Factor IX, APTT, Thrombin time, Factor XIII, Coagulation, Heparin-induced thrombocytopenia, Fibrinogen, Protein C, The Queen's Award for Enterprise: Innovation (Technology) (2011), Bleeding time, Factor, Activated protein C resistance, Factor X, Prothrombin time, Factor VIII, Prekallikrein, Factor V, Antithrombin, POC, Protein S, Factor XII, Factor XI, Fine chemical, Plasmin

The "2022-2026 Global Coagulation Testing Lab and POC Market: US, Europe, Japan--Supplier Sales and Shares, Volume and Sales Segment Forecasts, Competitive Strategies, Innovative Technologies, Instrumentation Review" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "2022-2026 Global Coagulation Testing Lab and POC Market: US, Europe, Japan--Supplier Sales and Shares, Volume and Sales Segment Forecasts, Competitive Strategies, Innovative Technologies, Instrumentation Review" report has been added to ResearchAndMarkets.com's offering.
  • This comprehensive seven-country report is designed to help current suppliers and potential market entrants identify and evaluate business opportunities emerging in the global coagulation testing market during the next five years.
  • New specific and sensitive markers of coagulation will be increasingly used on automated instrumentation.
  • Coagulation testing will also become more standardized, offering opportunities for quality control products and services.

New Data for Genentech’s Hemlibra (emicizumab-kxwh) Reinforce Safety Profile in People With Hemophilia A

Retrieved on: 
Monday, July 19, 2021
Biotechnology, Pharmaceutical, Health, Clinical trials, Blood, Branches of biology, Coagulation system, Anatomy, Haemophilia, Recombinant proteins, Factor VII, International Society on Thrombosis and Haemostasis, Haemophilia A, Factor V, Emicizumab, Recombinant factor VIIa, Hemlibra, hemophilia A, Genentech in hemophilia, Genentech, HEMLIBRA, HEMOPHILIA A, GENENTECH IN HEMOPHILIA, GENENTECH

The data were presented at the virtual International Society on Thrombosis and Haemostasis (ISTH) 2021 Congress, July 17-21.

Key Points: 
  • The data were presented at the virtual International Society on Thrombosis and Haemostasis (ISTH) 2021 Congress, July 17-21.
  • These results provide further confidence in Hemlibras favorable safety profile in people with hemophilia A with factor VIII inhibitors, who have historically faced significant treatment challenges.
  • Nearly one in three people with severe hemophilia A develop factor VIII inhibitors, antibodies that bind to and block the efficacy of replacement factor VIII.
  • Hemlibra has been approved in more than 100 countries worldwide for the treatment of people with hemophilia A with factor VIII inhibitors.

Enzyre announces strategic partnership with Takeda to accelerate development of pioneering diagnostic technology platform for hemophilia patients

Retrieved on: 
Thursday, March 4, 2021
Coagulation system, Blood, Anatomy, Body fluids, Coagulation, Factor VIII, Factor VII, Haemophilia, Factor V, Jeanne Lusher

Takeda confirmed the partnership by investing in Enzyre and joining its supervisory board.

Key Points: 
  • Takeda confirmed the partnership by investing in Enzyre and joining its supervisory board.
  • The Hemophilia Enzycard, the first product using Enzyre's proprietary Enzypad platform technology, can be used to determine the coagulation status of patients with hemophilia, a rare genetic disorder that affects an estimated 400,000 people worldwide.
  • [1] Those with hemophilia lack sufficient blood-clotting proteins, for example factor VIII (FVIII), causing them to bleed for a longer time after an injury compared to people without hemophilia.
  • Enzycard will enable patients to test in a home setting, immediately transferring coagulation status results to the patient's treating physician through a mobile phone app.

Enzyre announces strategic partnership with Takeda to accelerate development of pioneering diagnostic technology platform for hemophilia patients

Retrieved on: 
Thursday, March 4, 2021
Coagulation system, Blood, Anatomy, Body fluids, Coagulation, Factor VIII, Factor VII, Haemophilia, Factor V, Jeanne Lusher

Takeda confirmed the partnership by investing in Enzyre and joining its supervisory board.

Key Points: 
  • Takeda confirmed the partnership by investing in Enzyre and joining its supervisory board.
  • The Hemophilia Enzycard, the first product using Enzyre's proprietary Enzypad platform technology, can be used to determine the coagulation status of patients with hemophilia, a rare genetic disorder that affects an estimated 400,000 people worldwide.
  • [1] Those with hemophilia lack sufficient blood-clotting proteins, for example factor VIII (FVIII), causing them to bleed for a longer time after an injury compared to people without hemophilia.
  • Enzycard will enable patients to test in a home setting, immediately transferring coagulation status results to the patient's treating physician through a mobile phone app.

Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Factor VIII Activity Levels in 3x1013 VG/KG Cohort Through One Year Following Hemophilia A Gene Therapy

Retrieved on: 
Monday, December 7, 2020
Health, Genetics, Clinical trials, General Health, Pharmaceutical, Biotechnology, Branches of biology, Anatomy, Blood, Coagulation system, Recombinant proteins, Haemophilia, Coagulation, Alanine transaminase, Factor VIII, Factor V, Hematology, Alanine, the Alta study, the AFFINE study, giroctocogene fitelparvovec, Hemophilia A, Pfizer Rare Disease, Sangamo Therapeutics

As of the cutoff date of August 31, 2020, one patient had one target joint bleed requiring FVIII therapy, occurring after week 52.

Key Points: 
  • As of the cutoff date of August 31, 2020, one patient had one target joint bleed requiring FVIII therapy, occurring after week 52.
  • Among the five patients in the 3 x 1013 vg/kg dose cohort, four received corticosteroids for liver enzyme (alanine aminotransferase, ALT) elevations.
  • Hemophilia is a genetic hematological rare disease that results in a deficiency of a protein that is required for normal blood clotting clotting factor VIII in hemophilia A.
  • There can be no assurance that Sangamo will earn any additional milestone or royalty payments under the Pfizer collaboration.

Hemlibra (Emicizumab-kxwh) Drug Insight and Market Forecast 2020-2030 - ResearchAndMarkets.com

Retrieved on: 
Friday, October 9, 2020
Health, Pharmaceutical, Coagulation system, Health, Haemophilia, Branches of biology, Proteins, Recombinant proteins, Breakthrough therapy, Emicizumab, Factor VII, Haemophilia A, Clinical trial, Factor V

The "Hemlibra (Emicizumab-kxwh) - Drug Insight and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Hemlibra (Emicizumab-kxwh) - Drug Insight and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.
  • Hemlibra - Drug Insight and Market Forecast - 2030 report outlays comprehensive insights of the product based on routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients ages newborn and older with Hemophilia A (congenital factor VIII deficiency) with or without factor VIII inhibitors.
  • Further, it also consists of market assessments inclusive of the market forecast, SWOT analysis and detailed analyst views.
  • The report provides the clinical trials information of Hemlibra (emicizumab-kxwh) covering trial interventions, trial conditions, trial status, start and completion dates.

DGAP-News: Biotest AG: Biotest presented promising data on next generation recombinant Factor VIII at ISTH 2020

Retrieved on: 
Tuesday, July 21, 2020
Coagulation system, Branches of biology, Blood, International Society on Thrombosis and Haemostasis, Factor VIII, Peptide, Factor V

Biotest unveiled functional data from its new Factor VIII compounds at the ISTH 2020 congress (International Society on Thrombosis and Haemostasis).

Key Points: 
  • Biotest unveiled functional data from its new Factor VIII compounds at the ISTH 2020 congress (International Society on Thrombosis and Haemostasis).
  • Results from further animal models support a 4-fold extension of the half-life in blood circulation while maintaining the wild-type characteristics of activated Factor VIII with full in vivo functionality.
  • These benefits are based on the fusion of special Factor VIII sequences with four albumin-binding peptides shielding the active substance from degradation.
  • The ordinary and preference shares of Biotest AG are listed in the Prime Standard on the German stock exchange.

HEMA Biologics™ Announces FDA Approval of SEVENFACT® [coagulation factor VIIa (recombinant)-jncw] for Treatment and Control of Bleeding Episodes Occurring in Adult and Adolescent Hemophilia A and B Patients with Inhibitors

Retrieved on: 
Monday, April 6, 2020
Blood, Coagulation system, Branches of biology, Proteins, Factor VII, Recombinant factor VIIa, Haemophilia A, Haemophilia, Bleeding, Prothrombin complex concentrate, Factor IX, Factor V

"SEVENFACT is an innovative analog of human Factor VIIa and the result of a decades-long development effort across three continents.

Key Points: 
  • "SEVENFACT is an innovative analog of human Factor VIIa and the result of a decades-long development effort across three continents.
  • Several options have been made available for bleeding disorders in recent years, yet there were no new treatments for inhibitor-related bleeding.
  • "Patients and families impacted by inhibitors have limited options available for the treatment and control of bleeding.
  • Inhibitors are antibodies formed in response to treatment of hemophilia A or B with factor VIII or factor IX replacement, respectively.

Chugai’s Hemlibra Approved for Hemophilia A Without Inhibitors in Taiwan

Retrieved on: 
Wednesday, October 30, 2019
Biotechnology, Pharmaceutical, Health, Other Health, Coagulation system, Blood, Branches of biology, Medical specialties, Emicizumab, Coagulation, Factor VIII, Factor VII, Monoclonal antibody, Antibody, Factor V, Medication, Hemlibra, Chugai

TFDA has also approved additional dosing options of every two weeks or every four weeks in patients with hemophilia A with factor VIII inhibitors.

Key Points: 
  • TFDA has also approved additional dosing options of every two weeks or every four weeks in patients with hemophilia A with factor VIII inhibitors.
  • Hemlibra is a bispecific monoclonal antibody, which was developed using Chugai's proprietary antibody engineering technologies.
  • In doing so, Hemlibra provides the cofactor function of factor VIII in people with hemophilia A, who either lack or have impaired coagulation function of factor VIII1, 2).
  • Chugai, based in Tokyo, specializes in prescription pharmaceuticals and is listed on the 1st section of the Tokyo Stock Exchange.